The two faces of FBW7 in cancer drug resistance

Bioessays. 2011 Nov;33(11):851-9. doi: 10.1002/bies.201100101. Epub 2011 Aug 30.

Abstract

Chemotherapy is an important therapeutic approach for cancer treatment. However, drug resistance is an obstacle that often impairs the successful use of chemotherapies. Therefore, overcoming drug resistance would lead to better therapeutic outcomes for cancer patients. Recently, studies by our own and other groups have demonstrated that there is an intimate correlation between the loss of the F-box and WD repeat domain-containing 7 (FBW7) tumor suppressor and the incurring drug resistance. While loss of FBW7 sensitizes cancer cells to certain drugs, FBW7-/- cells are more resistant to other types of chemotherapies. FBW7 exerts its tumor suppressor function by promoting the degradation of various oncoproteins that regulate many cellular processes, including cell cycle progression, cellular metabolism, differentiation, and apoptosis. Since loss of the FBW7 tumor suppressor is linked to drug resistance, FBW7 may represent a novel therapeutic target to increase drug sensitivity of cancer cells to conventional chemotherapeutics. This paper thus focuses on the new functional aspects of FBW7 in drug resistance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Amyloid Precursor Protein Secretases / antagonists & inhibitors
  • Apoptosis
  • Benzenesulfonates / pharmacology
  • Biphenyl Compounds / pharmacology
  • Cell Cycle Proteins / genetics
  • Cell Cycle Proteins / metabolism*
  • Drug Resistance, Neoplasm*
  • F-Box Proteins / genetics
  • F-Box Proteins / metabolism*
  • F-Box-WD Repeat-Containing Protein 7
  • Gene Expression Regulation, Neoplastic*
  • Genes, Tumor Suppressor*
  • Humans
  • MAP Kinase Signaling System
  • MicroRNAs / genetics
  • MicroRNAs / metabolism
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Neoplasms / drug therapy
  • Neoplasms / genetics
  • Niacinamide / analogs & derivatives
  • Nitrophenols / pharmacology
  • Paclitaxel / pharmacology
  • Phenylurea Compounds
  • Piperazines / pharmacology
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Pyridines / pharmacology
  • Sorafenib
  • Sulfonamides / pharmacology
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism
  • Ubiquitin-Protein Ligases / genetics
  • Ubiquitin-Protein Ligases / metabolism*
  • Ubiquitination
  • Vincristine / pharmacology

Substances

  • ABT-737
  • Benzenesulfonates
  • Biphenyl Compounds
  • Cell Cycle Proteins
  • F-Box Proteins
  • F-Box-WD Repeat-Containing Protein 7
  • FBXW7 protein, human
  • MicroRNAs
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Nitrophenols
  • Phenylurea Compounds
  • Piperazines
  • Proto-Oncogene Proteins c-bcl-2
  • Pyridines
  • Sulfonamides
  • Tumor Suppressor Protein p53
  • Niacinamide
  • Vincristine
  • Sorafenib
  • Ubiquitin-Protein Ligases
  • Amyloid Precursor Protein Secretases
  • Paclitaxel